Why the study?
Catheter-directed thrombolysis has been proposed for pulmonary embolism with acute right ventricular dysfunction, prompting a review of current mainstream technologies, supporting evidence, and future research requirements.
This review discusses current technologies and the evidence base for catheter-directed thrombolysis in patients with pulmonary embolism and right ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
May inform decisions on catheter-directed thrombolysis for PE with RV dysfunction; leaves open need for randomized trials.
Pulmonary embolism is the third commonest cause of cardiovascular death globally. The majority of such patients present with low-risk features and can be managed with simple anticoagulation; however, a large group of patients exhibit evidence of right ventricular dysfunction on echocardiography or CT at the time of presentation and these patients are at risk of early haemodynamic compromise, particularly in those with abnormal cardiac biomarkers. Catheter-directed thrombolysis has been proposed as a treatment-strategy for patients with pulmonary embolism with evidence of acute right ventricular dysfunction. We review the current technologies in mainstream use, the evidence base in support of their use and discuss future research requirements in this area.
No takes yet. Share an insight, caveat, or question.
Sharp et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: